Hui Yun Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hui Yun Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Gang Wu
Huazhong University of Science and Technology
1 shared publicationLin Jing Yuan
Sun Yat-sen University Cancer Center
1 shared publicationMei Ying Zhang
Sun Yat-sen University Cancer Center
1 shared publicationPin Dong Li
State Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangdong, 510060, China
1 shared publicationWen Jie Zhang
Huazhong University of Science and Technology
1 shared publicationXiao Fang Ying
Sun Yat-sen University Cancer Center
1 shared publication
Latest Publications
- 10 June 2012
- Published by Springer Nature in Medical Oncology
- Vol. 29 (5) , 3070-3076
Overexpression of RPS6KB1 predicts worse prognosis in primary HCC patients
RPS6KB1 (ribosomal protein S6 kinase, 70 kDa, polypeptide 1) plays a key role in regulating protein translation. The role of RPS6KB1 in HCC (hepatocellular carcinoma) has not been fully investigated. This study was undertaken to determine the clinicopathological features and prognostic value of RPS6KB1 in HCC. We examined RPS6KB1 expression in 30 paired liver cancer tissues and adjacent noncancerous tissues by reverse transcription real-time PCR and Western blotting. In addition, we analyzed RPS6KB1 expression in 87 HCC samples by immunohistochemistry. The expression of RPS6KB1 was significantly increased in cancer tissues. Clinicopathological analysis showed that the expression of RPS6KB1 was significantly correlated with tumor size, histopathologic classifications, and serum alpha-fetoprotein (AFP). Kaplan–Meier survival curves revealed that increased expression of RPS6KB1 correlated with poor prognosis of HCC patients. RPS6KB1 expression was an independent prognostic marker for overall survival of HCC patients by multivariate analysis. Our data suggest that RPS6KB1 may play an important role in the progression of HCC and could serve as a potential molecular target for HCC therapy.
- 10 June 2012
- Published by Springer Nature in Medical Oncology
- Vol. 29 (5) , 3070-3076
Overexpression of RPS6KB1 predicts worse prognosis in primary HCC patients
RPS6KB1 (ribosomal protein S6 kinase, 70 kDa, polypeptide 1) plays a key role in regulating protein translation. The role of RPS6KB1 in HCC (hepatocellular carcinoma) has not been fully investigated. This study was undertaken to determine the clinicopathological features and prognostic value of RPS6KB1 in HCC. We examined RPS6KB1 expression in 30 paired liver cancer tissues and adjacent noncancerous tissues by reverse transcription real-time PCR and Western blotting. In addition, we analyzed RPS6KB1 expression in 87 HCC samples by immunohistochemistry. The expression of RPS6KB1 was significantly increased in cancer tissues. Clinicopathological analysis showed that the expression of RPS6KB1 was significantly correlated with tumor size, histopathologic classifications, and serum alpha-fetoprotein (AFP). Kaplan–Meier survival curves revealed that increased expression of RPS6KB1 correlated with poor prognosis of HCC patients. RPS6KB1 expression was an independent prognostic marker for overall survival of HCC patients by multivariate analysis. Our data suggest that RPS6KB1 may play an important role in the progression of HCC and could serve as a potential molecular target for HCC therapy.